IL-18 derived from microwave-ablated osteosarcoma facilitates antitumor response
Journal for ImmunoTherapy of Cancer · 2026-07 · 14 (7) · e014796
DOI: 10.1136/jitc-2026-014796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.07.2026. Verfasst von Jielong Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, South China University of Technology, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Osteosarcoma, Interleukin-18, Microwaves, Bone Neoplasms. Die Arbeit nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangdong Provincial Key R&D Program in Priority Areas, Guangdong Medical Science and Technology Research Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Osteosarcoma (OSA) is the most common primary malignant bone tumor in children and adolescents, while no further improvement in survival has been achieved in the past few decades. Microwave ablation (MWA) is an emerging thermal therapy to ablate malignant bone tumors that induces antitumor immunity, while intrinsic mechanisms remain elusive. This study uncovered that MWA treatment promoted interleukin (IL)-18 expression and enhanced the dendritic cell (DC) functions, as well as CD8 + T cells infiltration. Combining IL-18 and anti-programmed cell death protein 1 (PD-1) displayed the additive tumor suppression effects.
Methods
MWA treated OSA was co-cultured with bone marrow dendritic cells (BMDC) in vitro. RNA-sequencing was performed to analyze the intrinsic mechanism of BMDC after stimulated with MWA treated OSA. Mouse model of primary osteosarcoma of the femur was established for in vivo immune response evaluation, and this model was used to measure the additive tumor eradication of IL-18 and anti-PD-1 combination therapy.
Results
MWA promoted the activation, antigen uptake and antigen cross-presentation of BMDCs. Mouse models demonstrated that MWA treatment could elevate the proportion of CD8 + T cells and CD11c + DCs both in tumors and draining lymph nodes. The tumor suppression was mediated through the release of IL-18 by MWA-treated OSA and interaction with the IL-18 receptor on DCs, which was reversed after anti-IL-18 antibodies application. Besides, IL-18 cytokine exerted the tumor eradication effect and showed the additive role against OSA when combining anti-PD-1 therapy.
Conclusions
Our study demonstrated a critical role of IL-18-mediated signaling in the induction of protective immune responses against OSA, which provided a novel mechanism to the explanation of MWA-induced immune activation, and IL-18 cytokine treatment could be considered a feasible, effective therapeutic approach for OSA in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
- Department of Orthopaedics Oncology, Guangdong Provincial People's Hospital Affiliated to Southern Medical University, Guangzhou, Guangdong, China.
- Department of Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands luck_2001@126.com zhaomanzhi@gdph.org.cn c.schliehe@erasmusmc.nl.
- Guangdong Provincial People's Hospital Department of Respiratory and Critical Care Medicine, Guangzhou, Guangdong, China luck_2001@126.com zhaomanzhi@gdph.org.cn c.schliehe@erasmusmc.nl.
- School of Medicine, South China University of Technology, Guangzhou, Guangdong, China luck_2001@126.com zhaomanzhi@gdph.org.cn c.schliehe@erasmusmc.nl.
Förderung
- Guangdong Provincial Key R&D Program in Priority Areas
- Guangdong Medical Science and Technology Research Foundation
- National Natural Science Foundation of China
- 2023 Clinical feature technology program of Guangzhou, China
Zitieren
APA
Zhou, J., Zhang, Y., Yang, W., Wang, X., Li, M., Yao, M., Huang, W., Chu, X., Schliehe, C., Zhao, M., & Zhang, Y. (2026). IL-18 derived from microwave-ablated osteosarcoma facilitates antitumor response. Journal for ImmunoTherapy of Cancer, 14(7), e014796. https://doi.org/10.1136/jitc-2026-014796
Vancouver
Zhou J, Zhang Y, Yang W, Wang X, Li M, Yao M, et al. IL-18 derived from microwave-ablated osteosarcoma facilitates antitumor response. Journal for ImmunoTherapy of Cancer. 2026;14(7):e014796. doi:10.1136/jitc-2026-014796
BibTeX
@article{Zhou2026,
author = {Zhou, Jielong and Zhang, Yunhui and Yang, Wenjie and Wang, Xin and Li, Mei and Yao, Mengyu and Huang, Wenhan and Chu, Xiao and Schliehe, Christopher and Zhao, Manzhi and Zhang, Yu},
title = {IL-18 derived from microwave-ablated osteosarcoma facilitates antitumor response},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {7},
pages = {e014796},
doi = {10.1136/jitc-2026-014796}
}
EUVIMED